Int. Journal of Clinical Pharmacology and Therapeutics, Volume 49 - June (371 - 381)

Population pharmacokinetics of amikacin in a Korean clinical population
S.B. Jang1, Y.J. Lee1, M.S. Park2, Y.G. Song3, J.-H. Kim4, H.K. Kim5, B.S. Ahn5, K. Park1
1 Department of Pharmacology and 2 Pediatrics, 3 Internal Medicine, 4 Laboratory
Medicine in Gangnam Severance Hospital, 5 Department of Pharmacy in Gangnam
Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

Add to Cart  

 

DOI 10.5414/CP201520

Abstract

Objective: This study aimed at investigating the influence of demographic and clinical covariates on the population pharmacokinetics of amikacin in Korean patients from routinely collected therapeutic drug monitoring data. Materials and methods: Pharmacokinetics was studied in 305 adult Korean patients who received amikacin 125 – 1,000 mg once-daily or everyother- day. Peak and trough plasma levels of steady state were measured. Patients were randomized into an index dataset (n = 197) and a validation dataset (n = 108). Covariates were selected in a step-wise approach using NONMEM 7 software. The predictive performance of the model was evaluated by the percent prediction error and the percent coverage of 95% population prediction interval. Results: The covariates significantly influencing amikacin pharmacokinetics were creatinine clearance (p < 0.0001) and ward setting (p = 0.0017) for clearance, and body weight (p < 0.0001) and presence of cholecystitis (p = 0.0135) for volume of distribution. The estimates of pharmacokinetic parameters for a typical individual were 2.82 l/h for clearance, and 18.04 l for volume of distribution. Inter-individual variability (CV%) was 31% for clearance. The mean (SD) of percent prediction errors was 2.1 (26.4)% for peak and –121.5 (460.3)% for trough concentrations. Percent coverage of 95% PPIs for peak and trough concentrations were above 80%. Conclusions: The population pharmacokinetic model developed in this study may be used as a basis for finding optimal amikacin dosing in a Korean patient population without a significant bias. Further studies will be needed to validate these results.

Author Details

Authors

Departments

  • 1 Department of Pharmacology and
  • 2 Pediatrics,
  • 3 Internal Medicine,
  • 4 Laboratory
    Medicine in Gangnam Severance Hospital,
  • 5 Department of Pharmacy in Gangnam
    Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

Address

Kyungsoo Park, MD, PhD
Department of Pharmacology
Yonsei University
College of Medicine
134 Shinchon-dong, Seodaemun-gu,
Seoul 120-752, South Korea
Email: [email protected]

Citation

S.B. Jang, Y.J. Lee, M.S. Park, Y.G. Song, J.-H. Kim, H.K. Kim, B.S. Ahn and K. Park.Population pharmacokinetics of amikacin in a Korean clinical population. 2011; 49: 371-381. doi: 10.5414/CP201520.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart